How effective is eltrombopag for the treatment of chronic immune thrombocytopenia (ITP) in adults?

Updated: Nov 30, 2019
  • Author: Perumal Thiagarajan, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print


Eltrombopag is an oral nonpeptide thrombopoietin receptor agonist that interacts with the transmembrane domain of the thrombopoietin receptor and induces megakaryocyte proliferation and differentiation. It has been shown to increase the platelet count in refractory ITP and in thrombocytopenia associated with hepatitis C–induced cirrhosis. It will most likely also be effective in thrombocytopenia due to other causes, by stimulating megakaryocytes.

Eltrombopag is approved for treatment of refractory chronic ITP in patients who are at increased risk of bleeding because of their platelet count and clinical condition. It has also proved useful as bridging therapy for surgery, to provide a temporary pre-procedure boost in platelet count for patients with ITP who do not normally require therapy. [28]

Eltrombopag is given in doses of 25-75 mg daily. The adverse effects include hepatotoxicity, worsening of cataracts, and increased bone marrow reticulin fibers.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!